Thousand Oaks biotechnology company Amgen Inc. and Santa Monica cancer drug developer Kite Pharma Inc. announced today that they entered into a deal to develop and market cancer immunotherapies using Amgen’s cancer targets and Kite’s technology platform, Reuters reports. Read more about Kite Pharma’s recent endeavors in the Los Angeles Business Journal.